Intravacc B.V.

Originating from the Institute for Translational Vaccinology (Intravacc), Intravacc B.V., a private company with limited liability (B.V.), was established on 1 January 2021. Intravacc B.V. is one of the world's leading organisations in translational vaccinology and continues to move forward with its vision and mission to reduce global disease burden through innovative technology.

Role of Intravacc in VAC2VAC

Intravacc will be involved in developing physico-chemical and immunochemical models (Work Package 1 and Work Package 2) for conformational fingerprinting of protein antigens to ensure preservation of B-cell epitopes as well as immunochemical methods to monitor antigen degradation. In addition, Intravacc will be leader of Work Package 3 and will as such coordinate the activities of the partners involved in this WP.  Within WP3, Intravacc will be involved in the development of a tetanus- or diphtheria toxoid-specific T cell hybridoma activation assay and a cell-based test to assess the toxicity of C. perfringens C non-inactivated antigen.  In Work Package 4, Intravacc will focus on the investigation of the effects of canine Leptospira vaccines on APC using a systems immunology approach with the aim to identify biomarkers suitable for the determination of vaccine quality.  Once biomarkers are known, Intravacc will assist in developing specific assay in the context of WP3.

Partner representatives

Photo_Bernard MetzDr. Bernard Metz received his master's degree in chemistry from the University of Groningen in 1998 and obtained his PhD on Structural Characterisation of Diphtheria toxoid at the University of Utrecht in 2005. He has an extensive track record in vaccine characterisation and assay development. He identified formaldehyde-induced modifications by mass spectrometry, discovering novel covalent modifications in proteins but also developed immunochemical and physicochemical assays that were predictive for potency. Besides this, his research interests are in the area of molecular biology and systems vaccinology.




Arjen SlootsDr. Arjen Sloots obtained his PhD at the University of Frankfurt in 2004. His field of expertise is vaccine development, immunomodulation by bacterial pathogens and innate immunity. At Intravacc, he is responsible for Intravacc's 3R research activities and actively involved in the development of cell-based in vitro models for consistency testing of vaccines. Within the VAC2VAC project, he is the work package leader of Work Package 3 and a member of the Steering Committee.